

Anti-KIR3DL2/CD158k Antibody (Lacutamab)

Introduction

Lacutamab (IPH4102) is a novel anti-inflammatory drug targeting immune receptor molecules. KIR3DL2 Lacutamab is a humanized monoclonal antibody (mAb) produced in CHO cells by recombinant technology. Lacutamab can be used for the study of cutaneous T-cell lymphoma.

Product parameters

Alternative Names	IPH4102, IPH 4101, IPH41
Target Accession	P43630
Target	KIR3DL2 / CD158k
CAS number	2187368-16-5
Molecular Weight	144.52 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

